Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124717483 | 12471748 | 3 | F | 20160422 | 20160712 | 20160616 | 20160718 | EXP | FR-JNJFOC-20160607425 | JANSSEN | 59.30 | YR | A | F | Y | 0.00000 | 20160718 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124717483 | 12471748 | 1 | SS | CAELYX | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | N | N | 0 | 33 | MG | LIPOSOME INJECTION | ||||||
| 124717483 | 12471748 | 2 | SS | CAELYX | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | N | N | 0 | 33 | MG | LIPOSOME INJECTION | ||||||
| 124717483 | 12471748 | 3 | SS | CAELYX | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | FIRST COURSE, 33 MG | N | N | 0 | 20 | MG/KG | LIPOSOME INJECTION | |||||
| 124717483 | 12471748 | 4 | PS | CAELYX | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | SECOND COURSE, 33 MG | N | N | 50718 | 20 | MG/KG | LIPOSOME INJECTION | |||||
| 124717483 | 12471748 | 5 | SS | GEMZAR | GEMCITABINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | FIRST COURSE, 1640MG PER INTAKE ON D1, D8, D15 | 0 | 1000 | MG/M**2 | UNSPECIFIED | |||||||
| 124717483 | 12471748 | 6 | SS | GEMZAR | GEMCITABINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | SECOND COURSE, 1640MG PER INTAKE ON D1, D8, D15 | 0 | 1000 | MG/M**2 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124717483 | 12471748 | 1 | Lymphoma |
| 124717483 | 12471748 | 2 | Lymphoma |
| 124717483 | 12471748 | 3 | Lymphoma |
| 124717483 | 12471748 | 4 | Lymphoma |
| 124717483 | 12471748 | 5 | Lymphoma |
| 124717483 | 12471748 | 6 | Lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124717483 | 12471748 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124717483 | 12471748 | Neuropathy peripheral | |
| 124717483 | 12471748 | Off label use | |
| 124717483 | 12471748 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124717483 | 12471748 | 1 | 20160603 | 0 | ||
| 124717483 | 12471748 | 2 | 20160617 | 0 | ||
| 124717483 | 12471748 | 3 | 20160422 | 0 | ||
| 124717483 | 12471748 | 4 | 20160506 | 0 | ||
| 124717483 | 12471748 | 5 | 20160226 | 20160311 | 0 | |
| 124717483 | 12471748 | 6 | 20160325 | 20160408 | 0 |